Do you want to read an article? Please log in or register.
CheckMate 8HW: Nivolumab plus ipilimumab demonstrates durable benefit in MSI-H/dMMR metastatic CRC
Gastrointestinal Cancer
CHICAGO 2025
Related content
ESMO 2024
Skin Cancer
CheckMate 067: Sustained survival benefit with nivolumab plus ipilimumab and nivolumab monotherapy versus ipilimumab in patients with advanced melanoma
Skin Cancer
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
J Clin Oncol
Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C, Grob JJ, Ejzykowicz F, Moshyk A, Garcia-Horton V, Zhou ZY, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Patel D, Sakkal LA, Tawbi H, Schadendorf D
doi: 10.1200/JCO.24.01125
COMMENTED
Genitourinary Cancer
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Ann Oncol
Tannir NM, Albigès L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER, Porta C, George S, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Grünwald V, Rini BI, Jiang R, Desilva H, Federov V, Lee CW, Motzer RJ
doi: 10.1016/j.annonc.2024.07.727
Genitourinary Cancer
Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial
Eur Urol
Galsky MD, van der Heijden MS, Powles T, Claps M, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Ürün Y, Ye D, Valderrama BP, Tomita Y, Jiang R, Filian J, Wang L, van Kooten Losio M, Sonpavde G
doi: 10.1016/j.eururo.2025.04.019
Skin Cancer
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
J Clin Oncol
Long GV, Larkin J, Schadendorf D, Grob JJ, Lao CD, Márquez-Rodas I, Wagstaff J, Lebbé C, Pigozzo J, Robert C, Ascierto PA, Atkinson V, Postow MA, Atkins MB, Sznol M, Callahan MK, Topalian SL, Sosman JA, Kotapati S, Thakkar PK, Ritchings C, Pe Benito M, Re S, Soleymani S, Hodi FS
doi: 10.1200/JCO.24.00400
Lung, Respiratory and Thoracic Cancer
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01
Eur J Cancer
Tanaka H, Makiguchi T, Tozuka T, Kawashima Y, Oba T, Tsugitomi R, Koyama J, Tambo Y, Ogusu S, Saiki M, Gyotoku H, Hasegawa T, Miyauchi E, Sonoda T, Saito R, Nakatomi K, Sakatani T, Kudo K, Tsuchiya-Kawano Y, Nishio M
doi: 10.1016/j.ejca.2024.115117
Skin Cancer
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
N Engl J Med
Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG, Postow MA, Gaudy-Marqueste C, Medina T, Lao CD, Walker J, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Sandhu S, Lebbé C, Ascierto PA, Long GV, Ritchings C, Nassar A, Askelson M, Benito MP, Wang W, Hodi FS, Larkin J, CheckMate 067 Investigators
doi: 10.1056/NEJMoa2407417
Skin Cancer
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients
Eur J Cancer
Robert C, Long GV, Larkin J, Wolchok JD, Hassel JC, Schadendorf D, Hodi FS, Lebbé C, Grob JJ, Hyngstrom JR, Wagstaff J, Chesney J, Butler MO, Bechter O, Márquez-Rodas I, Pavlick AC, Durani P, Pe Benito M, Wang P, Postow MA, Ascierto PA
doi: 10.1016/j.ejca.2024.115119
Lung, Respiratory and Thoracic Cancer
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
J Clin Oncol
Awad MM, Forde PM, Girard N, Spicer J, Wang C, Lu S, Mitsudomi T, Felip E, Broderick SR, Swanson SJ, Brahmer J, Kerr K, Saylors GB, Chen KN, Gharpure V, Neely J, Balli D, Hu N, Provencio Pulla M
doi: 10.1200/JCO-24-02239